If you are training and also taking a GLP-1 medication prescribed through an online platform, one question is worth asking before any training question: how much review actually stood between your intake form and your prescription? Recent reporting on one large telehealth company put a number on that gap, and while the allegations are unproven and denied, the four checkpoints they describe are the ones that matter to anyone on these drugs. This is general health information, not medical advice, and nothing here should be used to change a prescription.
Table of Contents
- What prompted this
- Nobody has weighed you
- Labs ordered is not labs read
- The pause between doses is the safety feature
- Who reads it when you say something is wrong
- What to ask your telehealth provider
- Training while on a GLP-1
- How to report a reaction so it counts
- The other thing these platforms collect
- Questions people ask
What prompted this
On July 20, 2026, the health-news outlet STAT published an investigation reporting that clinicians at the telehealth company LifeMD were pushed to see more patients and issue prescriptions faster, with little screening and follow-up. Five former employees were interviewed; two of them said providers were at times expected to review the cases of 25 people an hour, working only from intake forms patients had completed themselves. That is roughly two minutes a case, and the queue described included both new patients and refills that stepped a patient up to a higher dose.
LifeMD strenuously denies the allegations; its chief executive said the company’s objective “has not been to run a pill mill.” No court or regulator has found anything, no class action over prescribing exists, and two of the underlying accounts come from lawsuits brought by former executives. A fuller account is at Did LifeMD Rush GLP-1 Prescriptions? What Ex-Workers Say.
The useful part for a reader is not the company. It is that obesity medicine has a handful of steps that take longer than two minutes and do not tolerate being skipped — and the reported accounts line up against those steps almost exactly. Four of them are worth knowing whoever prescribes for you.
Nobody has weighed you
A GLP-1 prescription is meant to rest on a documented weight and body mass index. In an office, somebody measures you. On an asynchronous platform, those numbers are digits you typed into a form, and a fast file review does not check them against anything.
For a runner this cuts in an unexpected direction. Endurance athletes routinely sit at the low end of population weight ranges, and BMI is a crude instrument for anyone carrying more muscle than average. A platform that treats a self-reported number as the whole eligibility question is equally incapable of catching someone who overstated a weight and someone whose weight is fine but whose relationship with food is not. Which leads directly to the screening question.
Screening for disordered eating is the check most worth caring about in an endurance population. Former staff in the reporting said providers were discouraged from asking questions they considered medically relevant — including history, other conditions and eating-disorder screening — on the reasoning that extra questions delay care. In a sport where restriction is normalised and relative energy deficiency is a recognised problem, an appetite-suppressing drug issued without that conversation is the wrong tool handed to the wrong person.
Labs ordered is not labs read
Baseline bloodwork — commonly a metabolic panel, thyroid function and HbA1c — exists to catch the conditions that make these medications risky for a particular person. Former employees said prescriptions were sometimes issued before results came back, or before a clinician looked at them.
That distinction is easy to miss as a patient, because you experience both versions identically: you get a lab order, you go, you get a prescription. The difference is whether anyone read the result before the prescription issued. If you cannot tell from your own records which happened, that is a reasonable thing to ask.
The pause between doses is the safety feature
These medications are deliberately started low and stepped up slowly. It is tempting to read the escalation schedule as a calendar — four weeks here, four weeks there — but the protection is not the interval. It is what is supposed to happen inside it: somebody checks whether you tolerated the last dose before you go up.
Former employees described refill queues approved in batches. Batching removes the check and leaves the calendar, which looks the same from the outside and is not the same thing at all. Step-ups are where the serious gastrointestinal, pancreatic and renal problems tend to surface, which is exactly why the pause exists.
If you are also training hard, you have a second reason to care. Appetite suppression plus a training load is a straightforward route to underfuelling, and the dose increase is the moment that gets worse. Sharply reduced intake, unusual fatigue on easy runs, or a heart rate that will not come down are all worth reporting rather than absorbing.
Who reads it when you say something is wrong
The fourth checkpoint is the one that decides whether the other three ever mattered. Severe vomiting, dehydration, or abdominal pain that could indicate pancreatitis are time-sensitive. Former staff said patient messages were routed through medical assistants rather than straight to a clinician, which could leave a reported symptom sitting for days.
Where that is how a platform works, the delay is itself the harm, regardless of how good the eventual answer is. It is worth knowing, before you need it, what the escalation path looks like on the service you use — and it is worth remembering that a messaging queue is not an emergency service. Severe symptoms belong with urgent care or emergency services, not a support inbox.
What to ask your telehealth provider
- Did a licensed clinician review my history, or did the intake form alone produce the prescription?
- Were my baseline labs reviewed before the prescription was issued?
- Was I screened for other conditions, interacting medications, and a history of disordered eating?
- Is each dose escalation reviewed individually, or applied on a schedule?
- If I report a side effect, who reads it first, and how quickly does it reach a clinician?
- Am I receiving the FDA-approved branded medication or a compounded version — and which?
None of these is an accusation. They are the questions any prescriber should be able to answer about their own process, and a service that answers them clearly is telling you something useful.
Training while on a GLP-1
This is general information about things worth watching, not a training prescription, and it does not replace advice from your own clinician.
- Fuelling is the whole problem. A drug that reduces appetite does not reduce the energy a training week costs. Intake becomes a deliberate decision rather than a signal you can wait for.
- Protein and strength work protect lean mass. Rapid weight loss from any cause takes muscle with it unless both are maintained.
- Hydration matters more than usual, particularly alongside gastrointestinal side effects.
- Dose-increase weeks are the ones to be conservative in, not the ones to test a new session on.
- Track the boring signals — resting heart rate, sleep, easy-run effort. Those move before you notice anything consciously.
How to report a reaction so it counts
If you have a severe or persistent reaction, get medical care first. Afterwards, consider reporting it to the FDA’s MedWatch programme, which is the route through which adverse events enter the federal safety data — patient reports are accepted, not only clinician ones. Keep your prescription records, visit notes and platform messages; they are the only durable record of what was asked and when.
For context on where the regulators have actually been active: the FDA sent warning letters to more than 50 compounders in September 2025, to 30 telehealth companies on March 3, 2026, and to a further 25 in June 2026, all over misleading claims about compounded semaglutide and tirzepatide. Those concern marketing rather than prescribing pace, and no warning letter to LifeMD has been identified in that wave.
The other thing these platforms collect
One footnote that has nothing to do with dosing and is worth knowing anyway. The intake questionnaire is a marketing surface as well as a clinical one, and separate litigation has focused on what those pages transmit.
Attorneys are currently investigating potential cases against LifeMD for alleged privacy violations in California, including its Rex MD and ShapiroMD brands. The question is whether the intake questionnaires passed a visitor’s own answers — weight-loss goals, symptoms, treatment inquiries — to third-party advertising networks before that visitor ticked the box agreeing to the Terms, Privacy Policy, Notice of Privacy Practices and telehealth consent, and before any account existed. It reaches people who only got as far as answering a few questions and then stopped — not customers — and is limited to California residents who started a questionnaire on or before June 14, 2026 who never accepted the terms, created an account or made a purchase.
No complaint has been filed, no class has been certified, and nothing has been proven. The published criteria are on the LifeMD data privacy investigation page. The general lesson holds for any health site: the questions you answer before you agree to anything are the ones answered with the least protection.
Questions people ask
Is online GLP-1 prescribing legal?
Yes. Asynchronous care, where a clinician reviews a written intake without a live video visit, is a recognised and lawful way to practise in most states, and it is what lets telehealth reach people who cannot easily get to an office. The contested question raised by recent reporting is not legality but pace.
What did the reporting about LifeMD actually say?
On July 20, 2026 the health-news outlet STAT reported that five former employees said clinicians were pushed to work faster than they thought was clinically responsible, with two describing an expectation of reviewing up to 25 patient cases an hour from self-completed intake forms. LifeMD strenuously denies it, no regulator has acted, and there is no class action. These are unproven allegations.
Should I stop my GLP-1 because of a news story?
No. Do not stop or change a prescribed medication on your own. Raise concerns with a licensed clinician, and if you are having a severe or persistent reaction, seek medical care.
What baseline tests are usually associated with starting a GLP-1?
Commonly a metabolic panel, thyroid function and HbA1c, alongside a documented weight and body mass index and a review of personal and family history. What is appropriate is a clinical decision for your own prescriber, not a checklist to self-apply.
How do I report a side effect to the FDA?
Through MedWatch, the FDA’s adverse event reporting programme. Reports from patients and clinicians are how adverse events enter the federal safety data. Reporting is not a substitute for seeking medical care.
This article is general health information and is not medical advice, a diagnosis, or a treatment recommendation. It does not establish a clinician-patient relationship. Do not start, stop or change any medication based on it — talk to a licensed clinician. The allegations described are unproven, LifeMD denies them, and no court or regulator has made any finding. RunningCardio is not affiliated with any company named here.
